clinical trial · NCT07230353
A Phase 1b Open-label Study to Evaluate Safety of Plamotamab in Participants With Rheumatoid Arthritis
Xencor, Inc.·phase1·recruiting·n = 68
Rheumatoid ArthritisPlamotamab
brief summary
The purpose of this study is to determine the safety and tolerability of plamotamab in patients with rheumatoid arthritis. Participants will be given XmAb13676 subcutaneously (SC) by injection under the skin.
started
Oct 21, 2025
primary completion
Jun 1, 2028
completion
Jun 1, 2028
last updated
Apr 14, 2026
detailed description
This is a Phase 1b study to determine the safety, tolerability, pharmacokinetic (PK), and pharmacodynamics (PD), and immunogenicity of plamotamab in adult participants with moderately to severely active RA. This is an open label dose optimization trial with approximately 68 participants assigned to different dose escalation cohorts.
official title
A Phase 1b, Open-label, Dose-Escalation Trial to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Plamotamab in Participants With Rheumatoid Arthritis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol